INVESTORS.ADURO.COM SERVER
I found that a single root page on investors.aduro.com took six hundred and fifty-six milliseconds to download. We could not detect a SSL certificate, so in conclusion our web crawlers consider this site not secure.
Internet Protocol
128.177.96.16
HTML TITLE
Investor Relations Aduro BiotechDESCRIPTION
Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The companys lead candidate an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration. August 14, 2015. August 10, 2015. Aduro Biotech Announces Second Quarter 2015 Financial Results. August 10, 2015. View all Press Releases. August 12, 2015.PARSED CONTENT
The domain has the following in the homepage, "Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials." We analyzed that the web site also stated " The companys lead candidate an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration." It also stated " Aduro Biotech Announces Second Quarter 2015 Financial Results."